×
About 1,483 results

ALLMedicine™ Apolipoprotein A-I Center

Research & Reviews  573 results

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
https://clinicaltrials.gov/ct2/show/NCT04216342

May 20th, 2022 - Cardiovascular disease (CVD) is one of the leading causes of death worldwide and elevated levels of cholesterol and triglycerides on plasma lipoproteins are major contributing risk factors. Therapeutic agents that increase High Density Lipoprotein...

Lack of ApoA-I in ApoEKO Mice Causes Skin Xanthomas, Worsening of Inflammation, and Inc...
https://doi.org/10.1161/ATVBAHA.122.317790
Arteriosclerosis, Thrombosis, and Vascular Biology; Busnelli M, Manzini S et. al.

May 20th, 2022 - HDL (High-density lipoprotein) and its major protein component, apoA-I (apolipoprotein A-I), play a unique role in cholesterol homeostasis and immunity. ApoA-I deficiency in hyperlipidemic, atheroprone mice was shown to drive cholesterol accumulat...

ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
https://doi.org/10.1007/s11883-022-01025-7 10.1016/j.jacc.2005.07.006 10.1161/01.CIR.34.4.679 10.1056/NEJMoa064278 10.1038/nm.2937 10.1161/ATVBAHA.107.145672 10.1016/j.jacc.2014.02.615 10.1016/j.numecd.2013.05.002 10.1016/S0140-6736(75)92376-4 10.1016/S0022-2275(20)43114-1 10.1172/JCI42946 10.1161/CIRCULATIONAHA.112.108753 10.1056/NEJM199908053410604 10.1056/NEJM198711123172001 10.1056/NEJMoa1001282 10.1016/j.ahj.2018.09.011 10.1016/S0735-1097(86)80293-5 10.1056/NEJMoa1107579 10.1056/NEJMoa1300955 10.4065/83.4.470 10.1111/ijcp.12089 10.1093/eurheartj/ehl392 10.1016/S2213-8587(19)30003-8 10.1056/NEJMoa0706628 10.1056/NEJMoa1206797 10.1056/NEJMoa1609581 10.1161/CIRCULATIONAHA.108.772665 10.1056/NEJMoa1706444 10.1172/JCI26206 10.1194/jlr.R800097-JLR200 10.1161/ATVBAHA.109.186031 10.1161/JAHA.118.011792 10.2174/13816128113199990298 10.1016/j.atherosclerosis.2015.08.027 10.1016/j.ahj.2016.07.005 10.1056/NEJMoa1001689 10.1056/NEJMoa1409065 10.1016/S2213-8587(15)00126-6 10.1161/ATVBAHA.109.199158 10.1016/j.cmet.2016.01.005 10.1161/01.ATV.0000092328.66882.F5 10.1016/S0022-2275(20)33893-1 10.1016/j.jacc.2004.06.070 10.1007/978-3-319-09665-0_21 10.1161/01.ATV.0000184760.95957.d6 10.1172/JCI114558 10.1161/CIRCRESAHA.119.312617 10.1161/01.CIR.0000070934.69310.1A 10.1161/01.CIR.0000013424.28206.8F 10.1016/S0022-2275(20)32212-4 10.1161/ATVBAHA.107.148403 10.1001/jama.297.15.jpc70004 10.1161/CIRCULATIONAHA.113.002671 10.1161/CIRCULATIONAHA.113.002683 10.1161/01.CIR.103.15.1949 10.1016/0021-9150(85)90063-2 10.1161/hc2501.092494 10.1161/01.CIR.90.4.1935 10.1001/jama.290.17.2292 10.1001/jamacardio.2018.2112 10.1016/j.atherosclerosis.2016.05.038 10.1093/eurheartj/ehu171 10.21037/cdt.2017.02.01 10.21037/cdt.2017.01.01 10.1001/jamacardio.2018.2121 10.1016/S0002-8703(02)00128-X 10.1002/jat.3264 10.1161/CIRCULATIONAHA.111.066589 10.1161/CIRCGENETICS.111.960773 10.1161/ATVBAHA.114.303720 10.1002/jcph.194 10.1161/ATVBAHA.118.310538 10.1161/CIRCULATIONAHA.116.025687 10.1016/j.ahj.2020.10.052 10.1056/NEJMra1216063 10.1161/01.CIR.0000145170.22652.51 10.1001/jama.295.13.jpc60002 10.1016/j.jacc.2016.10.029 10.1161/01.CIR.87.6.1781 10.1016/S0002-9343(98)00041-2 10.1160/TH08-07-0469 10.1016/j.cardiores.2005.11.003 10.1161/ATVBAHA.113.303044 10.1016/S1050-1738(01)00163-3 10.1006/bbrc.1997.6286 10.1172/JCI116349 10.1016/S0021-9150(99)00279-8 10.1016/j.atherosclerosis.2016.10.042 10.1194/jlr.M800578-JLR200 10.1007/s40261-017-0506-3 10.1016/S0021-9258(20)80707-8 10.1056/NEJMoa0904327 10.1016/j.jacc.2007.12.010 10.1161/JAHA.115.002171
Current Atherosclerosis Reports; Kalayci A, Gibson CM et. al.

May 8th, 2022 - The elevated adverse cardiovascular event rate among patients with low high-density lipoprotein cholesterol (HDL-C) formed the basis for the hypothesis that elevating HDL-C would reduce those events. Attempts to raise endogenous HDL-C levels, howe...

The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloido...
https://doi.org/10.1080/13506129.2022.2070741
Amyloid : the International Journal of Experimental and C... Cohen OC, Blakeney IJ et. al.

May 4th, 2022 - Hereditary apolipoprotein A-I (AApoAI) amyloidosis is a rare heterogeneous disease with variable age of onset and organ involvement. There are few series detailing the natural history and outcomes of solid organ transplantation across a range of c...

Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the ...
https://doi.org/10.1186/s12933-022-01484-x 10.1111/j.1365-2796.2006.01617.x 10.1042/CS20080050 10.1161/HYPERTENSIONAHA.118.11130 10.1152/ajprenal.00039.2014 10.1152/ajpendo.00396.2016 10.1042/CS20120661 10.1016/j.atherosclerosis.2017.12.021 10.1016/j.freeradbiomed.2012.03.002 10.3389/fphar.2012.00055 10.1007/s13105-012-0154-2 10.1111/j.1365-2362.2011.02558.x 10.1016/j.metabol.2013.01.011 10.1016/j.numecd.2013.12.009 10.1016/j.numecd.2011.03.001 10.1016/j.metabol.2007.12.003 10.1111/j.1753-0407.2011.00138.x 10.1089/jwh.2010.2453 10.1038/srep30051 10.1042/CS20140566 10.1161/CIRCULATIONAHA.119.044562 10.1001/archinte.167.10.1068 10.1371/journal.pmed.1001779 10.1007/s00103-015-2297-0 10.1371/journal.pone.0240413 10.1080/10408363.2018.1428526 10.1038/ncomms13357 10.1186/1471-2261-12-102 10.1093/gerona/glp005 10.1161/JAHA.117.005520 10.1093/clinchem/40.1.18 10.1016/j.atherosclerosis.2007.11.022 10.1016/j.plipres.2012.11.001 10.1038/srep09886 10.1038/tpj.2012.9 10.1161/01.CIR.98.19.2088 10.1016/j.metabol.2006.01.020 10.1016/0006-2952(95)02395-X 10.1056/NEJMoa043175 10.1016/j.exger.2015.09.014 10.1016/j.atherosclerosis.2020.12.005 10.1016/j.metabol.2009.04.003 10.1074/jbc.RA120.013700 10.1016/j.metop.2021.100114 10.1186/s12902-020-00563-y 10.1161/ATVBAHA.117.310071 10.3390/ijms17070999 10.1016/j.biopha.2019.108973 10.2174/13816128113199990559 10.1093/ije/dyx206
Cardiovascular Diabetology; Seyed Khoei N, Wagner KH et. al.

Apr 20th, 2022 - Mildly elevated bilirubin, a by-product of hemoglobin breakdown, might mitigate cardiometabolic risk factors including adiposity, dyslipidemia, and high blood pressure (BP). We investigated the cross-sectional relationship between (total) bilirubi...

see more →

Clinicaltrials.gov  9 results

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
https://clinicaltrials.gov/ct2/show/NCT04216342

May 20th, 2022 - Cardiovascular disease (CVD) is one of the leading causes of death worldwide and elevated levels of cholesterol and triglycerides on plasma lipoproteins are major contributing risk factors. Therapeutic agents that increase High Density Lipoprotein...

Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)
https://clinicaltrials.gov/ct2/show/NCT02713880

May 5th, 2021 - Diseases of diverse etiology can be correlated to the term "polyneuropathy"(PNP). The pathogenesis may be of inflammatory, autoimmune, metabolic, toxic or hereditary nature. Careful clinical and electrodiagnostic assessment, with attention to the ...

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study
https://clinicaltrials.gov/ct2/show/NCT00728910

Feb 29th, 2016 - Objectives Summary * To investigate whether the progressive addition of a fibrate and niacin to baseline statin therapy will improve apolipoprotein A-I kinetics, postprandial lipidemia, and postabsorptive lipoproteins and metabolism in adult men a...

Theobromine, Vascular Function and Intestinal apoA-I Production
https://clinicaltrials.gov/ct2/show/NCT02209025

Sep 7th, 2015 - Rationale: Despite successful efforts to lower atherogenic serum low-density lipoprotein (LDL) cholesterol concentrations, a substantial residual cardiovascular risk remains. An additive strategy to further lower this residual risk may be via rais...

The Effects of Fat and Theobromine on apoA-I
https://clinicaltrials.gov/ct2/show/NCT02085109

Aug 5th, 2014 - Rationale: Despite successful efforts to lower atherogenic serum low-density lipoprotein (LDL) cholesterol concentrations, a substantial residual cardiovascular risk is still present. An additive strategy to further lower this residual risk may be...

see more →

News  11 results

ApoA-I Therapies Flop for Plaque Reduction
https://www.medpagetoday.com/cardiology/atherosclerosis/74221

Jul 25th, 2018 - Action Points Two studies of recombinant apolipoprotein A-I (the major HDL apolipoprotein) products failed to show an effect on coronary plaque volume assessed by intravascular ultrasound (IVUS). Note that based on these studies, the development o...

No Plaque Reduction With Mimetic HDL Agent in ACS: CARAT Phase 2 Trial
https://www.medscape.com/viewarticle/877757

Mar 27th, 2017 - WASHINGTON, DC — Infusing an engineered HDL-cholesterol mimetic into patients who recently have had acute coronary syndrome (ACS) did not reduce the volume of plaque in arteries as measured by intravascular ultrasound (IVUS) compared with placebo,...

Favorable Lipid Changes Seen with Baricitinib
https://www.medpagetoday.com/rheumatology/arthritis/62498

Jan 12th, 2017 - Action Points Baricitinib, an investigational reversible inhibitor of tyrosine kinases JAK 1 and JAK2 signaling, increases the level of serum lipids, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-...

Mono/Combo Therapy Improves HDL in Early RA
https://www.medpagetoday.com/rheumatology/arthritis/59675

Aug 14th, 2016 - Action Points Note that this secondary analysis of a clinical trial in patients with rheumatoid arthritis found that decreases in inflammatory markers were associated with improvement in HDL function. While the mechanism is not entirely clear, imp...

Pyloric Stenosis Linked to Low Serum Lipids in Infants
https://www.medscape.com/viewarticle/809710

Aug 20th, 2013 - Low serum lipids are a risk factor for infantile hypertrophic pyloric stenosis (IHPS), according to a genetics study published in the August 20 issue of JAMA. A Multifactorial Condition Heritability exceeds 80% for IHPS, but little is known about ...

see more →